← All trials
NCT06435221
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- May 30, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 650
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Achieve Life SciencesLead sponsor
- Achieve Life SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.